Quadrise (LON: QED) non-executive director Dilip Shah had sold 1,000 shares at 6.55p on 17 January 2025 and was transferred 35 million shares and not 34.16 million shares in December as previously announced. Because of his failure to comply with company share trading policy he has stepped down from the board. The share price increased 9.8% to 2.8p.
Pulsar Helium (LON: PLSR) says that the Jetstream #5 appraisal well at the Topaz project in Minnesota has encountered an additional pressurized gas influx at approximately 2,857 feet in depth. This new gas zone is estimated at around 1,292 psi, the highest recorded to date at Topaz. The drilling of the hole continues before moving to the next well. The share price improved 7.98% to 57.5p.
Biopesticides developer Eden Research (LON: EDN) has achieved a second regulatory authorisation this week with fungicide Novellus+ gaining approval in Chile. This is used in wine and table grapes to control grey mould (Botrytis cinerea) and powdery mildew (Uncinula necator). Earlier in the week Mevalone was granted approval in France to use on grapes to control downy and powdery mildew. The share price rose 8.2% to 3.3p.
FALLERS
Shareholders in Indus Gas (LON: INDI) voted in favour of leaving AIM and that will happen on 23 January. JP Jenkins will provide a matched bargains facility. The share price slumped 32.4% to 1.85p.
Galantas Gold (LON: GAL) has been hit by profit-taking after the jump following news that it is acquiring 100% of the Andacollo Oro gold project in Chile. The share price slipped 15.2%, but it has trebled over the week.
Sunrise Resources (LON: SRES) says that the option period for the sale of Hazen project without being exercised. Sunrise Resources will retain the project, which is non-core. The share price dipped 9.09% to 0.025p.
ValiRx (LON: VAL) has entered a nine-month, evaluation and material transfer agreement with The Royal Institute for the Advancement of Learning/McGill University and The Institute for Research in Immunology, and Cancer-Commercialization of Research in Canada. This will evaluate a RNA Helicase inhibitor. ValiRx will own the evaluation results, and they can be swapped for a 15% take in the company set up to commercialise the technology. The share price fell 4.88% to 0.39p.